Clinical Trial Results:
A double-blind, placebo-controlled efficacy (as assessed by post-bronchodilator FEV1) and safety study of 5 mg RO3300074 once-daily for 2 years in subjects with smoking-related, moderate-to-severe COPD with emphysema receiving concurrent optimal COPD drug therapy.
Summary
|
|
EudraCT number |
2006-002525-23 |
Trial protocol |
GB HU CZ IS LV IT |
Global completion date |
24 May 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Jul 2016
|
First version publication date |
04 Jul 2015
|
Other versions |
|
Summary report(s) |
NB19751_redacted synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.